Objective: Endothelial function is improved by L-arginine (L-arg) supplementation in preclinical and clinical studies of mildly diseased vasculature; however, endothelial function and responsiveness to L-arg in severely diseased arteries is not known. Our objective was to evaluate the acute effects of catheter-directed L-arg delivery in patients with chronic lower extremity ischemia secondary to peripheral arterial disease.
Nitric oxide (NO) is synthesized in virtually all cells by a family of calcium calmodulin-dependent enzymes called nitric oxide synthases (NOSs).
1 L-arginine (L-arg)
serves as the substrate of NOS and thus as a precursor to NO. 2 NO stimulates soluble guanylyl cyclase, leading to an increased concentration of cyclic guanosine monophosphate, and modifies proteins of all classes by S-nitroyslation. In the vasculature, NO plays a pivotal role in the regulation of smooth muscle tone and proliferative capacity and of endothelial function via its antithrombotic, anti-inflammatory, and antiatherosclerotic properties. 3 Consistent with this construct, endothelial dysfunction is believed to represent the earliest abnormality in the development of atherosclerosis. 4 L-arg supplementation improved endothelial function in preclinical and ex vivo studies. [5] [6] [7] For example, in a rat thrombosis model, the addition of high-dose L-arg to urokinase resulted in greater increases in endothelium-dependent relaxation (EDR) than urokinase alone. 5 Similarly, endothelial dysfunction was ameliorated in a porcine model with the regional infusion of L-arg combined with standard thrombolytic therapy. 6 Plasma levels of NO metabolites (NO x ), a marker of endothelial NOS activity, were increased by L-arg infusion in both studies. We examined previously EDR in explanted human arteries from lower extremity amputation specimens. 7 This showed that diseased human peripheral arterial segments retained a low level of endothelial responsiveness that was augmented by L-arg supplementation in an ex vivo model. Taken together, these studies suggest L-arg supplementation enhances endotheliaL-dependent relaxation through NO-dependent mechanisms in healthy animal vessels and in diseased explanted human arteries. Previous data raised the possibility that vascular function may be improved by L-arg supplementation even in severely diseased vessels in vivo. The method of determination of EDR in human arteries in vivo has been published by our group. 8 The objective of this study was to evaluate L-arg supplementation in arteries of patients with chronic lower extremity ischemia secondary to peripheral arterial disease (PAD).
METHODS
Protocol and study participants. This protocol was approved by the Cleveland Clinic and University Hospitals Case Medical Center Institutional Review Boards. Details of the protocol, patient recruitment, and baseline clinical studies have been previously published. 8 Briefly, study participants were recruited from outpatient clinics. The study enrolled patients with chronic lower extremity occlusive disease who required lower extremity diagnostic angiography, most in preparation for a percutaneous intervention or surgical revascularization. A total of 25 patients were studied. The analysis in this report includes patients from the previous study, 8 with the exclusion of three patients (n ¼ 22) because equipment failure during the studies precluded obtaining all of the data. The target extremity was defined as the leg with the most severe symptoms. All participants were provided written informed consent for study participation, including performance of intravascular ultrasound (IVUS) imaging concurrent with angiography, infusion of arterial agonists, and infusion of L-arg. The inclusion criteria were (1) age $18 years; (2) symptoms of intermittent claudication, rest pain, or minor tissue loss (Rutherford category I-V) 9 ; (3) noninvasive vascular laboratory evidence of PAD incorporating studies such as ankle-brachial indices, pulse volume recording, or arterial duplex imaging; and (4) angiographic demonstration of a patent segment of the superficial femoral artery allowing IVUS catheter introduction and Doppler FloWire (Volcano Corporation, Rancho Cordova, Calif) measurements.
Exclusion criteria were (1) acute limb ischemia; (2) contraindication to angiography (creatinine >2.5 mg/dL), except for dialysis patients; and (3) instances in which concurrent oral anticoagulant therapy could not be safely withheld.
Clinical data were entered in an encrypted intranet case report form and archived electronically into a dedicated Health Insurance Portability and Accountability Act-compliant Oracle (Oracle Corp, Redwood Shores, Calif) database during a single office visit. Results of previous laboratory studies were abstracted from the electronic database.
Preprocedural laboratory studies performed for this study (if not <2 months) included fasting blood glucose, HbA 1c (in diabetic patients), cholesterol profile, homocysteine, and high-sensitive C-reactive protein. These assays were performed by clinical chemistry using standard assays.
Doppler FloWire, EDR, and EDR measurements. This methodology is fully explained in a recent article, including derivation of all EDR calculations. 8 Briefly, participants underwent diagnostic angiography through a contralateral femoral artery approach. An appropriate sized sheath (eg, 40-cm, 6F Raabe sheath; Cook, Inc, Bloomington, Ind) was placed up-and-over the aortic bifurcation and into the patent common or superficial femoral artery just above the sites of interrogation, but ensuring that it was not obstructing the flow. A heparin bolus (3000-5000 U) was given after long sheath insertion. Standard diagnostic arteriographic imaging was performed. The wire was then exchanged to a 0. , and 10 À4 were prepared immediately before the procedure and delivered to the operating room. Ach was infused for 1 minute at each concentration. 10, 11 Electrocardiogram-gated systolic IVUS axial diameter measurements were made 30 seconds after each infusion dose to measure EDR. Vessel area changes were calculated using measurements of lumen change. Simultaneous measurements in average peak velocity (APV) were recorded. After a washout period of 2 to 3 minutes, the participant received 50, 100, or 500 mg L-arg supplementation infused via an end-hole catheter proximal to the IVUS interrogation over 30 seconds. L-arg was prepared at room temperature by the research pharmacy. No placebo was used because this would have lengthened the procedure by an additional 20 minutes and increased procedural risk. EDR was reassessed immediately as described above.
Heparinized saline (20 mL) was used to wash out any remaining Ach or L-arg before nitroglycerine infusion. EIR to confirm smooth muscle function in the media was executed with a single dose of nitroglycerine (200 mg) with IVUS diameter measurements 30 seconds after infusion. All procedures were performed in the endovascular operating room with cardiopulmonary monitoring and conscious sedation.
IVUS and virtual histology vessel analysis. IVUS images were obtained during 10-cm pulL-backs of the target artery and processed using previously established methods. 12, 13 The luminal and mediaL-adventitial borders were detected using a deformable model algorithm with available user correction when needed. IVUS measurements were calculated in accordance with the standards published by the American College of Cardiology and the European Society of Cardiology. 14 These methods were similar to those used in the Reversal of Atherosclerosis With Aggressive Lipid Lowering (REVERSAL) 15 and A Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound-Derived Coronary Atheroma Burden (ASTEROID) 16 trials. The accuracy and reproducibility of these methods have been validated previously. 17 Biochemical analysis. Changes in local levels of NO were determined using a Sievers 280i NO detector (GE Analytical Instruments, Boulder, Colo) that is sensitive to the picomole level for liquid samples. A baseline venous blood sample was drawn from the antecubital location. Serial arterial samples were taken at the level of IVUS interrogation via a guiding catheter or sheath side port. This allowed us to compare systemic vs local NO levels. Baseline arterial levels were also compared with post-L-arg infusion levels. The plasma components of these samples were evaluated using the chemiluminescent assay for NO x by an experienced laboratory technician. Plasma protein was precipitated by treatment with 2 volumes of ethanol at 0 C for 30 minutes, followed by centrifugation at 14,000g for 5 minutes. The supernatant was injected into a purge vessel containing the reagents for nitrite or nitrate determination: Nitrite was converted to NO by reduction with potassium iodide in acetic acid at room temperature, and nitrate by reduction with vanadium chloride in HCl at 90 C. NO released was carried to the NO detector by a stream of helium. Mass spectrometry analyses were performed by the Mass Spectrometry II Core services at the Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio. The first panel consisted of ornithine, lysine, arg, and citrulline. The second panel consisted of monomethylarginine (MMA), symmetric dimethylarginine (SDMA), and asymmetric dimethylarginine (ADMA). These panels were quantified using the liquid chromatography/electrospray ionization/tandem mass spectrometry methods developed and used currently in the Core (Waters 2690 Separations Module; Waters, Milford, Mass).
Statistical analysis. Data are reported as means 6 standard error except when otherwise noted. In some cases, notably for flow rates and average peak velocity, values are reported as percentage change to normalize for variability in vessel size between patients. We used a level of a ¼ .05 for all statistical tests. Dose response curves for hemodynamics and blood flow were analyzed by twoway repeated-measures analysis of variance (ANOVA), and the Fisher least significant difference test was used for post hoc analysis. Single comparisons were made with a two-tailed Student paired or unpaired t-test. Statistical analysis was performed with GraphPad Prism 6.02 for Windows software (GraphPad Software, Inc, La Jolla, Calif).
RESULTS
Angiography and the endothelial function protocol were performed in 22 patients. The protocol using IVUS, Doppler FloWire, and agonist infusion added w20 minutes to each angiographic case. No adverse events related to the study protocol occurred in these patients, including the absence of allergic reactions or hemodynamic instability.
L-arg effects on EDR. We measured endothelial function via response of the artery to Ach infusion and delineated changes in cross-sectional area, velocity of blood flow (cm/s), and a calculated limb volumetric flow (Q ¼ area Â velocity ¼ mL/min). Lower extremity arteries showed minor changes in cross-sectional area in response to the Ach infusion. 8 However, after L-arg infusion, endothelial responsiveness significantly increased over baseline values. After the 50 mg L-arg infusion (n ¼ 3), area increases were 4.5%, 1.2%, and 3.3%.
At 100 mg (n ¼ 10), increases were 3.4%, 3.3%, and 4.0%. At 500 mg (n ¼ 9), increases were 8.1%, 12.2%, and 11.3%. Calculated together, these significant increases in area in response to L-arg were 5.4% at Ach À6 , 6.7% at Ach À5 , and 6.8% at Ach À4 (P < .05 by two-way ANOVA; Fig 1 and dose responses are combined and compared with pre-Larg findings, Q increases by 25.3%, À5.3%, and 15.4% with increasing Ach levels. A two-way ANOVA found a significant effect of Ach (P < .005) for APV and Q (Fig 2) . Arterial smooth muscle responsiveness was confirmed by infusion of a NO donor (nitroglycerin) and was intact in all vessels (EIR, 137% 6 28% Q increase).
Serum metabolites. L-arg delivered via the catheter could be measured to have increased in the serum within minutes after infusion. Mass spectrometry evaluation of serum obtained via arterial sampling showed significant increases of local arginine levels by 43.6% 6 13.0% for all patients (Fig 3) . The metabolite ornithine also significantly increased by 23.2% 6 10.3% with L-arg infusion. Lysine increased by 15.8% 6 9.5% and citrulline increased by 22.1% 6 11.6%, but neither of these values reached statistical significance. SDMA and ADMA showed significant increases of 19.1% 6 9.1% and 18.73% 6 9.1%, respectively. MMA showed an increase of 25.9% 6 13.6% after the L-arg infusion.
Chemiluminescence. We measured levels of NO x in these patients at three distinct locations and time points.
Venous NO x levels obtained via venipuncture were compared with arterial NO x obtained at the end of the arterial sheath. Venous NO x approximated arterial NO x before L-arg infusion. After L-arg infusion, arterial NO x levels increased by 125% from baseline (Fig 4) . 
DISCUSSION
Endothelial dysfunction is a common process in patients with atherosclerosis. In this study, we examined endothelial function directly in the arterial segments affected by atherosclerosis. This study represents, to our knowledge, the first report showing that catheterdirected L-arg therapy improves endothelial function in the short-term in diseased human lower extremity arteries. This study represents a follow-up from the previous report in which the method to study endothelial function in humans in vivo was determined. Using Ach infusion as a baseline condition and varying the amount of L-arg, we were able to investigate the endothelial response to L-arg and ultimately NO and its NO x . We also demonstrated that the improvement in EDR was the likely result of an NO-dependent process, and in particular, that the benefits of L-arg were likely mediated by enhanced NO bioactivity. These results support the application of biological therapies to enhance endothelial function and NO generation even in the setting of advanced atherosclerosis and chronic ischemia. The effects of exogenous L-arg supplementation have been tested by various means in animal models. Girerd et al 20 showed that intravenous L-arg administration augmented endothelium-dependent vasodilation of hind limb resistance vessels in anesthetized cholesteroL-fed rabbits. The hind limb vasodilator responses to incremental intra-arterial infusions of Ach and nitroprusside were studied before and during intravenous administration of L-arg, D-arg, or saline. Similar results were obtained by this group in a hypercholesteremic rabbit aorta model. 21 In vessels from hypercholesterolemic animals, L-arg potentiated the maximal response to acetylcholine and increased the sensitivity to Ach. Collectively these data suggested that atherosclerotic relaxations can be normalized by exposure to L-arg. Intravenous infusion of L-arg has also been studied in humans. Creager et al 22 L-arg vs placebo twice daily for 3 weeks. Flow-mediated dilation and blood chemistry were obtained at baseline and repeated after the treatment period. Baseline and follow-up levels of L-arg did not differ significantly between the two groups, and the HeartBar group had no improvement in flow-mediated dilation. A similar study with HeartBar supplementation assessed walking distance and quality of life as the end points. 25 After 2 weeks of treatment, pain-free walking distance and total walking distance both increased in the group consuming two HeartBars daily. An improvement in total walking distance was also observed in the group consuming one HeartBar daily. The effects were maintained after 10 weeks and were not observed in the placebo arm. The Nitric Oxide in Peripheral Arterial Insufficiency (NO-PAIN) study 26 was a prospective, single-center, randomized, double-blind, placebo-controlled study of the efficacy and safety of oral L-arg supplementation in patients with intermittent claudication. Study patients received oral L-arg (3 g/d) or placebo for 6 months. The primary end point was the change in the absolute claudication distance at 6 months. Blood chemistry markers, ankle-brachial index, and flow-mediated vasodilation of the brachial artery were also assessed at baseline and at 6 months. Their findings showed L-arg supplementation significantly increased plasma L-arg levels. However, plasma and urinary NO x and plasma citrulline formation were reduced or not improved compared with placebo. Absolute claudication distance improved in both the L-arg-treated and placebo-treated patients, but the improvement in the L-arg group was significantly less than that in the placebo group. Interestingly, both groups showed increases in claudication distances, and flow-mediated vasodilation in the L-arg group actually decreased after 6 months. These findings, however, deviated from the study's pilot data, 27 which examined similar end points after only 12 weeks of treatment. Ultimately, the group concluded that in patients with PAD, long-term oral administration of L-arg does not improve vascular reactivity or show laboratory evidence of increasing NO synthesis. But whether these results reflect limited bioavailability of L-arg with oral intake mandates further investigation. This study represents the first trial examining the effects of catheter-directed L-arg infusion in human lower extremity arteries. This modality of delivery augmented blood flow in the target vessel and increased local NO levels. The volumetric flow results obtained by our methods closely match those published previously using noninvasive methods. [28] [29] [30] The results are somewhat surprising given the severity of PAD and suggest that there is some functional endothelial reserve in these patients. Advanced clinical ischemia does not negate the possibility of pharmacologic intervention. Indeed, our study indicates a measure of vascular reserve in these patients that might be accessed or stimulated by agents that improve endothelial function by increasing NO bioactivity, including biopterin, ascorbate, and thioredoxin reductase inhibitors (auranofin). Still, one must view our results with caution. Short-term improvements in endothelial function by L-arg supplementation may not translate to the possibility of longterm pharmacotherapy for endothelial dysfunction. Our results show that L-arg supplementation increased levels of endogenous inhibitors of NOS (ADMA and SDMA). In addition, ornithine levels increased, which may be due to increased arginase activity. This is consistent with other investigators who have shown that arginase expression and levels may have a large role in endothelial dysfunction in patients with established cardiovascular disease. 31 Thus, L-arg supplementation in the setting of increased arginase could lead to uncoupling of NOS and oxidative stress in the endothelium. Our study has several limitations. The invasive nature of the protocol made patient recruitment somewhat selective and limited our sample size. There was variability in response to the Ach dosage before L-arg infusion in each group. Although there is no clear reason for this, it is likely reflective of the small sample size in the 50-mg L-arg group (n ¼ 3) and of the variability in the physiology of the patients themselves. Still, we have confidence that a 100-mg L-arg dose appears to be a suitable dose for further studies. We also did not establish any clinical end points (such as improvement in symptoms) beyond routine followup in the clinic to exclude adverse outcomes. Finally, the investigators were not blinded to the doses of L-arg or the orders in which the drug was administered; thus, there is the possibility of systemic observer bias due to learning effects. Furthermore, a placebo was not used because doing so would have lengthened the invasive procedure by at least 20 minutes, an amount that was deemed unacceptable. This pilot study was successful in establishing safety and dose ranges for future protocols.
CONCLUSIONS
Despite extensive atherosclerosis, endothelial function is intact in diseased lower extremity human arteries. Endothelial function can be improved, in the shortterm, by directly infusing L-arg. This improvement is secondary to increased NO bioactivity. Further studies of
